MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Neurocrine Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

106.99 -3.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

106.46

Max

110.59

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-27M

103M

Pardavimai

5.6M

628M

P/E

Sektoriaus vid.

33.617

63.778

Pelnas, tenkantis vienai akcijai

1.69

Pelno marža

16.425

Darbuotojai

1,800

EBITDA

-39M

152M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+48.73% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-04-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.8B

11B

Ankstesnė atidarymo kaina

110.3

Ankstesnė uždarymo kaina

106.99

Naujienos nuotaikos

By Acuity

50%

50%

173 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Neurocrine Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-01-28 00:03; UTC

Karštos akcijos

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2024-08-13 11:30; UTC

Svarbiausios naujienos

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Akcijų palyginimas

Kainos pokytis

Neurocrine Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

48.73% į viršų

12 mėnesių prognozė

Vidutinis 164.5 USD  48.73%

Aukščiausias 192 USD

Žemiausias 138 USD

Remiantis 22 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Neurocrine Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

22 ratings

17

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

109.68 / 114.425Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

173 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.